Irish biotech company Inflazome (inflazome.com) said on Friday that it expects to receive patents in the US and Europe for Inzomelid, its lead brain penetrant clinical candidate.

The company stated that the US Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant the patent application WO 2016/131098 as US 10,538,487 on 21 January 2020 and EP 3,259,253 on 15 January 2020 for Inzomelid.

According to the company, the US and European patents provide for compounds which have advantageous properties and show useful activity in the inhibition of NLRP3 inflammasome activation. Such compounds are useful in the treatment of Parkinson's, Alzheimer's and Motor Neuron Disease, in which inflammation arising from the NLRP3 inflammasome is implicated as a key factor.

These new patents strengthen the company's intellectual property portfolio that extends to 43 patent families, reinforcing the leading innovative position in discovering targeted therapies for inflammatory-driven diseases. The patent was licensed exclusively to Inflazome.